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Abstract
Background: Prostate cancer is frequently treated using external beam radiation therapy (EBRT). Prior to therapy,
the prostate is commonly implanted with a small number of permanent fiducial markers used to monitor the position
of the prostate during therapy. In the case of local cancer recurrence, high-intensity focused ultrasound (HIFU)
provides a non-invasive salvage treatment option. However, the impact of the fiducial markers on HIFU treatment has
not been thoroughly studied to date. The objective of this study was to experimentally investigate the effect of a
single EBRT fiducial marker on the efficacy of HIFU treatment delivery using a tissue-mimicking material (TMM).
Methods: A TMM with the acoustic properties of the prostate was developed based on a polyacrylamide hydrogel
containing bovine serum albumin. Each phantom was implanted with a cylindrical fiducial marker and then sonicated
using a 3.3 MHz focused bowl HIFU transducer. Two sets of experiments were performed. In the first, a single lesion
was created at different positions along either the anteroposterior or left-right axes relative to the marker. In the
second, a larger ablation volume was created by raster scanning. The size and position of the ablated volume were
assessed using a millimetre grid overlaid on the phantom.
Results: The impact of the marker on the position and size of the HIFU lesion was significant when the transducer
focus was positioned within 7 mm anteriorly, 18 mm posteriorly or within 3 mm laterally of the marker. Beyond this,
the generated lesion was not affected. When the focus was anterior to the marker, the lesion increased in size due to
reflections. When the focus was posterior, the lesion decreased in size or was not present due to shadowing.
Conclusions: The presence of an EBRT fiducial marker may result in an undertreated region beyond the marker due
to reduced energy arriving at the focus, and an overtreated region in front of the marker due to reflections.
Depending on the position of the targeted regions and the distribution of the markers, both effects may be
undesirable and reduce treatment efficacy. Further work is necessary to investigate whether these results indicate the
necessity to reconsider patient selection and treatment planning for prostate salvage HIFU after failed EBRT.
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Background
Prostate cancer is the most commonly occurring cancer
in men [1]. External beam radiation therapy (EBRT) is
frequently used as a definitive treatment for localised and
locally advanced prostate cancer. Prior to commencing
EBRT, permanent fiducial markers are commonly
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implanted into the prostate to increase the accuracy of
treatment as part of image-guided radiotherapy (IGRT).
These are used for localisation of the prostate, motion
and deformation tracking, and as reference points for
distance measurements [2, 3]. Despite the effectiveness of
EBRT, cancer can reoccur locally in the prostate in up to
30% of patients [4]. In such cases, further local treatment
using an alternative (salvage) therapy can be considered.
High-intensity focused ultrasound (HIFU) provides a
non-invasive salvage treatment option for patients with
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recurrence after EBRT. During HIFU treatment, an ultra-
sound beam is generated with energy sufficient to induce
tissue destruction within the focal volume by means
of thermal, mechanical, and cavitation effects [5]. The
ablated volume has a well-defined margin, which is one
of the main advantages of HIFU therapy. HIFU treatment
for prostate cancer can be delivered to the whole gland or
focally to only the cancerous lesion within the prostate.
The ablation is given in blocks in order to treat small vol-
umes of the prostate sequentially, so as to limit damage
to adjacent healthy tissue. Good local cancer control has
been reported by several studies [4, 6–9].
However, an open question remains as to the impact of
fiducial markers implanted during the EBRT procedure
on the efficacy of post-EBRT salvage HIFU treatments.
Typically, three gold fiducial markers in the shape of a
cylinder (approximately 3 mm in length and 1 mm in
diameter) are implanted in the prostate before the patient
undergoes EBRT planning, and remain permanently in the
prostate after the completion of the treatment [10]. As
the characteristic acoustic impedance of the gold marker
(ρ = 19300 kg/m3, c = 3240 m/s) is significantly higher
than the impedance of the prostate tissue (ρ = 1050
kg/m3, c = 1578 m/s), this could potentially lead to
distortion of the beam due to scattering or reflections
when obstructed by the marker, compromising treatment
efficacy.
Two previous studies have investigated the effect of low-
dose brachytherapy seeds on HIFU treatment with mixed
results [11, 12]. Brachytherapy seeds have a similar size
and acoustic impedance to gold fiducial markers, thus the
effect of the seeds on HIFU is likely to be similar. In 2003,
a feasibility study for the treatment of prostate cancer
using HIFU after brachytherapy failure was done by Seip
et al. [11]. By performing in vivo canine experiments, they
suggested that intraprostatic brachytherapy seeds have no
impact on HIFU therapy. However, in 2007, Chapman
et al. [12] performed lesioning experiments using ex vivo
bovine liver and showed that seeds in the pre-focal region
reduce HIFU lesion length and increase lesion variability,
with the greatest effect when they are positioned close to
the focus.
More recently, a series of simulations was used to inves-
tigate the impact of EBRT fiducial markers on HIFU treat-
ment, using a numerical model of the prostate containing
a single spherical or cylindrical fiducial marker [13]. The
results indicated that placing a marker in the pre-focal
region can induce a reduction in intensity of more than
30% of the homogeneous value, which will, in turn, cause
a reduction in the volume of the ablated region. The sim-
ulations showed that the marker’s effect depends on its
shape and distance from the focus of the transducer, with
its impact significantly increasing when placed within 5
mm of the focus [13].
Most recently, a study was done investigating the
effect of voxel masking in magnetic resonance-guided
HIFU due to the presence of biopsy markers [14].
The study suggested that the markers had a min-
imal impact on the size of the target volume but
that a smaller sonication on a marker might be more
problematic.
The aim of the current study was to experimentally
investigate the numerical results presented in [13]. Specif-
ically, to produce thermal lesions in a tissue-mimicking
material with and without a single EBRT fiducial marker
obstructing the HIFU beam, and to investigate any
changes in the size and position of the lesion due to the
presence of the marker.
Methods
Phantom fabrication
A tissue-mimicking material (TMM) with the properties
of the prostate was manufactured based on a polyacry-
lamide hydrogel (PAG) embedded with bovine serum
albumin (BSA), as proposed by Lafon et al. [15]. BSA is
a protein used as a temperature-sensitive indicator and
thus shows a localised response to HIFU treatment in
the form of an opaque lesion with a well-defined mar-
gin [16]. This TMM was chosen because its acoustic and
thermal properties are similar to that of human soft tis-
sue and can be tuned to match the desired properties
[17–19]. The material is stable at high temperatures and
pressures, and provides visible feedback of the lesion
created with HIFU.
Previously, both the acoustic and thermal properties
of BSA PAG have been characterised [15, 20]. Selected
parameters are presented in Table 1, with the proper-
ties of prostate tissue shown for reference. While most of
the TMM properties are close to those in prostate tissue,
the measured attenuation coefficient of the TMM with
either 9% BSA concentration [15] or 7% BSA concentra-
tion with increased acrylamide concentration and added
glass beads [20] are below or well above the median value
reported for the prostate. In order to suit the requirements
for a prostate phantom, the recipe reported by Khokhlova
et al. [21], who reported attenuation coefficient values in
gel with 7% BSA of about one-third of the value in tis-
sue, was modified as follows. First, the concentration of
BSA was increased in order to achieve higher attenua-
tion (it has previously been reported that the attenuation
increases linearly with the concentration of BSA [15]).
Second, the initial concentration of a 40% solution of acry-
lamide was increased to produce more stable phantoms,
as this is what determines the hardness and crosslinking
of the gel [22].
The final recipe for a 200 ml phantom with 14% BSA
concentration was as follows:
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Table 1 Sound speed c, density ρ , impedance z, and acoustic attenuation coefficient α for standard BSA PAGa , TM BSA PAGb with
increased acrylamide concentration and added glass beads, and the newly developed BSA PAG in comparison to the values for the
human prostatec
Material c (103 m/s) ρ (103 kg/m3) z (106 kg/m 2/s) α (dB/cm) f (MHz)
BSA PAG 1.54 ± 0.01 1.04 ± 0.02 1.60 ± 0.01 0.58 3.5
TM BSA PAG 1.58 ± 0.01 1.06 ± 0.01 1.67 ± 0.01 1.91 3.5
New BSA PAG 1.55 ± 0.02 1.09 ± 0.02 1.70 ± 0.02 1.10 3.5
Prostate 1.58 1.05 1.66 0.5-1.5 3.5
TM Tissue-mimicking, BSA Bovine Serum Albumin, PAG Polyacrylamide Hydrogel
aLafon et al. [15]
bChoi et al. [20]
cDuck [24]; Worthington et al. [30]
1. 14.000 g of BSA was dissolved in 143.22 ml of
degassed distilled water (71.61%) and then placed in a
vacuum chamber for 1 hour.
2. 40.00 ml of a 40% (w/v) solution of acrylamide/bis
19:1 (20%) was then added to the mixture, followed
by 20.00 ml of 1M TRIS buffer pH 8 (10%), and 1.68
ml of APS (0.84%).
3. The entire solution was placed in a vacuum chamber
for 1 hour for additional degassing.
4. Polymerization was finalised by adding 0.10 ml of
degassed TEMED (0.05%).
5. The solution was then transferred into 5 ml Leur Slip
Terumo syringes (used as moulds), and allowed to
polymerise under airtight conditions at a
temperature of 2°C overnight (the polymerization is
highly exothermic and can reach temperatures up to
80°C, thus refrigeration is necessary)
6. After fabrication, the phantoms were stored in a
vacuum-sealed bag and refrigerated at 2°C to prevent
microbial invasion.
Phantom characterisation
In order to characterise the acoustic properties of the BSA
PAG phantoms, two slabs with dimensions of 10 cm x 10
cm and thicknesses of 25 mm and 40 mm were made. The
density of the phantom was determined from measure-
ments of the mass and volume of the two samples and
was measured to be 1099.5 ± 18.0 kg/m3. Speed of sound
and attenuation measurements were performed using a
through-transmission substitution technique as described
in detail in section 3 of Zeqiri et al. [23]. Two transduc-
ers were used in transmission to cover a wider range of
frequencies, namely a 2.25 MHz unfocused PZT trans-
ducer (Panametrics-NDT, Olympus Industrial, Essex, UK)
with an outer diameter of 32 mm, and a 5.3 MHz PVDF
transducer (PA392, Precision Acoustics, Dorchester, UK)
with an outer diameter of 23 mm. The detector used was
a calibrated 0.5 mm PVDF needle hydrophone (PA2290,
Precision Acoustics, Dorchester, UK). The hydrophone
was placed aligned with the beam axis in the far-field
region of the field generated by the transducer. Each trans-
ducer was driven with a single cycle burst at its centre
frequency. Signals were acquired and digitised using an
oscilloscope (DPO5034B, Tektronix UK Ltd., Berkshire,
UK). The transmission through each of the samples and
through the direct water path was measured. The FFT
of the signals was obtained and the transmission loss
through each sample was calculated. To remove the effect
of interfacial losses, the attenuation coefficient was calcu-
lated from the ratio of the difference in transmission loss
through the two samples to the difference in their thick-
nesses. Each set of measurements was repeated four times
at different source - hydrophone distances, increasing
in steps of 10 mm. The measured frequency-dependent
attenuation coefficient was fitted with a power law of the
form α = α0f y over the frequency range from 1 to 9
MHz, where α0 = 0.1559 dB/cm/MHzy and y = 1.552
(R2 = 0.99). The attenuation measurements and power
law fit are shown in Fig. 1. At the frequency of interest (3.3
MHz), the attenuation coefficient was ∼1 dB/cm, which
is close to the previously reported values for the prostate
[13, 24]. For the calculation of the speed of sound, the time
of arrival of the pulses was determined from the time at
which the signal at the beginning of the pulse was visible
above the noise, with the acquisition synchronised with
signal generation. The measured speed of sound at room
temperature was 1550.5±1.5 m/s.
Experimental setup
A schematic of the experimental setup is shown in Fig. 2.
The experiments were performed in a scanning tank filled
with deionized water at room temperature (∼24-26°C).
The acoustic field was generated using a single-element
spherically focused HIFU transducer (H-101, Sonic
Concepts, Bothell, WA, USA) with an active diameter of
64 mm and focal length of 63.2 mm. The transducer was
driven at 3.3 MHz (the third harmonic) using a continu-
ous wave input signal generated by an arbitrary waveform
generator (33522A, Agilent Technologies, PaloAlto, CA,
USA) and amplified by an RF power amplifier (ENI A300,
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Fig. 1Measured acoustic attenuation coefficient in the
tissue-mimicking phantommade from a polyacrylamide hydrogel
containing bovine serum albumin. The data points represent the
experimental data, and the solid line is a power law fit with
parameters 0.156f 1.55
Electronics and Innovation, Rochester, NY, USA) before
transmission to the transducer via an impedance match-
ing network (H-101G Impedance Matching Network,
Sonic Concepts, Bothell,WA, USA). The drive voltage was
measured using a scope probe (N2863B, Agilent Tech-
nologies, PaloAlto, CA, USA) and an oscilloscope (DSO-X
3024A, Agilent Technologies, PaloAlto, CA, USA). The
BSA PAG phantom was held within a custom PMMA
mount and connected to a 3-axis manual positioning
Fig. 2 Schematic of experimental setup showing (1) the
high-intensity focused ultrasound transducer, (2) phantommount
containing the tissue-mimicking material with implanted fiducial
marker, (3) acoustic absorber used to prevent reflections, and (4)
3-axis manual positioning system
system with 0.01 mm positioning accuracy. An acoustic
absorber was placed at the rear wall of the tank to pre-
vent acoustic reflections. A peak-to-peak drive voltage of
112 V and a sonication time of either 10 s (single lesion
experiments) or 6 s (raster scan experiments) was used in
all reported experiments. These driving parameters were
shown to create repeatable thermal lesions in preliminary
measurements. The focal intensity was estimated using
a combination of experimental acoustic holography and
nonlinear modelling as reported in Kreider et al. [25]. In
water, the estimated intensity was ≈1400 W/cm2, while
in the BSA phantom, the estimated intensity was ≈1200
W/cm2. For comparison, the transducer in the clinically
used Sonablate 500 (SonaCare Medical LLC, Charlotte,
NC, USA) has a frequency of 4 MHz, element dimensions
of 22 mm by 30 mm, two fixed focal lengths of 30 mm and
40 mm, and pulse duration 3 s [26]. The focal intensity
reported ranges from 1000 to 2000 W/cm2 [27–29].
Experimental protocol - single lesion
Two sets of experiments were performed. In the first set
of experiments, the BSA PAG phantoms were cylindrical
in shape, with a diameter of 20 mm and a length of 30 to
50 mm. Before sonication, each phantom was implanted
with a single cylindrical marker (1 mm in diameter and 3
mm in length) made of stainless steel (ρ = 8000 kg/m3,
c = 5970 m/s), which was used to replicate the gold
EBRT fiducial markers used clinically. Due to a large num-
ber of experiments performed, it was cost prohibitive to
use clinical markers for the experiments. However, the
normal incidence pressure reflection coefficients of gold
and stainless steel in prostate tissue are 0.95 and 0.93,
respectively, thus the materials are acoustically very sim-
ilar. The markers were inserted into the phantoms using
a gauge 16 catheter needle (Catheter I.V., Insyte, 16 GA,
1.7 x 45 mm) modified with a copper wire used to push
the markers out of the needle. A laser cut PMMA grid
was used to allow precise alignment and needle orien-
tation. The markers were always inserted at right angles
to the beam axis. This orientation was chosen to mimic
the most common clinical scenario where the markers
are inserted transperineally, and the HIFU transducer is
positioned transrectally. In some phantoms, there was a
small amount of migration in themarker orientation when
the catheter was removed, however, this was similar to
the migration that occurs clinically. The phantom was
then mounted in the tank with the cylindrical axis of the
phantom aligned with the beam axis.
In each phantom, two lesions were created. First, a ref-
erence lesion was generated close to the edge of the phan-
tom without the marker obstructing the HIFU beam path.
Second, a lesion was generated with the transducer focus
placed at a specified distance from the marker (see Fig. 3).
For each phantom, the two lesions were always at the
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Fig. 3 Schematic showing how the shift in lesion position and
distance from the transducer focus to the marker were measured.
Note, the schematic is not to scale; reference lesions were
approximately 1 x 1 x 3 mm3
same depth, and sufficiently well separated to not affect
the generation of the second lesion. The focus position
was then systematically varied along either the anteropos-
terior or left-right axes relative to the marker in steps of
1 mm. In the anteroposterior direction (z-axis in Fig. 3),
31 different positions were tested, ranging from 10 mm
in front of the marker to 20 mm behind it. These experi-
ments were always conducted with the beam axis aligned
with the marker (i.e., with no offset in the left-right or
x-direction), and were repeated eight times. In the left-
right direction (x-axis in Fig. 3), 11 positions were tested
ranging from the centre of the marker to 10 mm to the
side. These experiments were conducted for 16 differ-
ent offsets in the anteroposterior direction, ranging from
5 mm in front of the marker to 10 mm behind. For this
arrangement, the sonications at each of the positions were
made only once.
After sonication, the volume and position of the pro-
duced lesions were measured to quantify the distortion
introduced by the marker in comparison to the refer-
ence lesion in that phantom. The lesion dimensions and
position were measured visually using a millimetre grid
printed on transparent paper positioned in front of the
phantom, with an uncertainty of ± 0.5 mm. The volume
was then calculated assuming an ellipsoid, where V =
4
3πabc with a, b, and c being the measured semi-axes of
the ellipsoid. The shift in lesion position was measured as
the distance between the ends of the lesions distal from
the transducer face, as shown in Fig. 3. The shift was
attributed a positive value if the lesion position moved
away from the transducer (in the positive z-dimension).
Experimental protocol - raster scan
In the second set of experiments, the BSA PAG phan-
toms were cuboids in shape, with dimensions of 3× 3× 5
cm3. Again, each phantom was implanted with a single
cylindrical marker as described in the previous section.
The transducer was then raster scanned across the tar-
get region to create a larger ablation volume in order to
mimic how the HIFU treatments are performed clinically.
The raster scans were performed along the x-axis (left-
right) for a fixed z-position relative to the marker, with
6 s on time, and 3 s off time. 21 different z-positions were
tested, ranging from 10 mm anterior to the marker to 10
mmposterior. For each raster scan at a fixed z-position, 12
sonications were performed with the position of the focus
for each sonication shifted by 1 mm in the x-direction.
Raster scans at each of the z-positions were conducted
once.
Results
Single lesion - offset along the anteroposterior axis
Figure 4 shows the change in volume and position of the
lesion as a function of the transducer focal position rela-
tive to the marker for an offset along the anteroposterior
axis. For comparison, the volume of the reference lesion
varied between 1 × 1 × 3 mm3 and 1 × 1 × 4 mm3,
and always occurred at the same axial position. When the
marker was positioned close to the transducer focus, the
ultrasound beam was strongly aberrated, and the lesions




Fig. 4 Change in the (a) lesion volume and (b) lesion position as a
function of the offset between the focal position and the marker,
when the focal position is translated along the anteroposterior
(z) axis. Each measurement was repeated 8 times, and the error bars
show one standard deviation. A negative change in volume indicates
the lesion volume was reduced, and a negative shift indicates the
lesion was shifted towards the transducer
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When the transducer focus was in front of the marker
(negative z-position in Fig. 4), the impact of the marker
on the lesion volume and position was noticeable up to an
offset of -7 mm. The lesion increased in volume (some-
times more than four-fold) and was shifted closer to the
marker due to reflections of the ultrasound energy from
the marker. When the transducer focus was positioned
at the marker, the lesion volume still increased due to
reflection, but there was no shift in lesion position. When
the transducer focus was positioned behind the marker
(positive z-position in Fig. 4), the impact of the marker
on the lesion volume and position was noticeable up to
an offset of 18 mm. The lesion decreased in volume and
was again shifted closer to the marker. This was due to a
reduction in energy arriving at the intended focus because







Fig. 5 Lesions produced in BSA PAG phantoms with the transducer focus positioned 10, 5, 3, 2, 1 mm in front of the marker (a-e), at the marker (f)
and 1, 2, 3, 5, 10, 20 mm behind the marker (g-l). The black broken line indicates that the photo was trimmed to fit both the marker and lesions
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reflectivity, as was previously mentioned. This is consis-
tent with the simulation results presented in Georgiou
et al. [13]. In the experiments, the shift in lesion position
was especially prominent for focal positions up to 4 mm
behind the marker, where the lesion was not produced at
the desired position but was instead shifted in front of
the marker.
Examples of the lesions produced at different marker
positions are shown in Fig. 5. Both the reference and dis-
torted lesion are shown in each photograph. The lesions
were produced with the transducer focus positioned 10,
5, 3, 2, 1 mm in front of the marker (a-e), at the marker
(f), and 1, 2, 3, 5, 10, 20 mm behind the marker (g-l). The
black broken line indicates that the photo was trimmed
to show both the marker and lesions within the figure.
As can be seen from the photos, the markers in each
phantom were positioned at slightly different angles due
to a slight migration of the marker during the insertion
procedure.
Single lesion - offset along the left-right axis
Figure 6 shows the change in the lesion volume as a func-
tion of the transducer focal position relative to the marker
for an offset along the left-right axis. Here, “at centre”
corresponds to the transducer focus placed in the centre
of the marker, and the zero position corresponds to the
focus placed at the edge of the marker. Although these
experiments were repeated for 16 different offsets in the
anteroposterior direction, the results are collated into two
groups based on the observed effect. As shown in Fig. 6a,
there was an increase in the lesion volume when the trans-
ducer focus was positioned between 5 mm in front of the
marker and 4 mm behind it, and within 3 mm of the edge
of the marker in the left-right direction. A decrease in
lesion volume was observed when the transducer focus
was positioned between 5 mm and 10 mm behind the
marker and within 6 mm of the marker edge. As the
beam width at the marker position increased the further
behind the transducer focus was placed, a larger offset
was required between the focus and the marker in the x-
direction to move the marker out of the beam path. These
results, combined with the ones obtained in the first set
of measurements, are in agreement with Georgiou et al.
[13], where the simulations predicted the effect to be sig-
nificant in an hourglass-shaped volume surrounding the
fiducial marker.
Raster scans
The experiment with the raster scans yielded results sim-
ilar to the single lesion experiments, but the range of
distances over which the effect was observed was slightly
smaller. This was more evident with the transducer focus
positioned behind the marker, where the effect dimin-
ished after 10 mm (compared to 17 mm in the single
b
a
Fig. 6 Change in the lesion volume as a function of the offset
between the focal position and the marker, when the focal position is
translated along the left-right (x) axis for a fixed position in the
anteroposterior axis. The results are grouped for (a) the transducer
focus positioned from 5 mm in front of the marker to 4 mm behind it
(average of 10 measurements), and (b) the transducer focus
positioned from 5 mm to 10 mm behind themarker (average of 6
measurements). The error bars show the standard deviation based on
the grouped measurement results
lesion experiment). The cause of this might be the reduced
sonication time (6 s vs 10 s for the single lesion exper-
iments), or that the neighbouring sonications partially
increased the temperature in the shadow zone behind
the marker, allowing a visible lesion to be generated even
when the beam path was partially occluded by the marker.
The results for several positions tested are shown in Fig. 7.
When the transducer focus was between 5 mm in front
and 2 mm behind the marker, the size of the ablated vol-
ume increased, with the ablation extending proximally to
the marker (Fig. 7b-g). When the transducer focus was
positioned further behind the marker, up to 7 mm, the
ablated volume decreased, with a noticeable gap distal to
the marker (Fig. 7h-i).
Discussion
Comparison with simulations
The experimentally measured changes in the lesion
volume and position were similar to the changes reported
in the simulation study presented in Georgiou et al.
[13]. In particular, the lesion volume increased when the











Fig. 7 Lesions produced in BSA PAG phantoms after raster scanning the transducer in the x-direction with the transducer focus positioned 10, 5, 2, 1
mm in front of the marker (a-d), at the marker (e) and 1, 2, 5, 7, 10 mm behind the marker (f-j)
transducer focus was positioned immediately in front of
the marker and reduced when positioned immediately
behind. The predicted focal shifts were also of a similar
magnitude (maximum shifts on the order of∼5mm), with
the largest effect observed when the marker was within 6
mm along the anteroposterior axis. This suggests that the
results are not strongly influenced by choices made in the
experimental design which differ between the simulations
and experiments.
Changes in volume could not be quantitatively
compared as in the numerical simulations only the -6dB
focal volume of the temporal-average intensity was cal-
culated (no thermal simulations were conducted), while
in the measurements the ablation volume was measured.
The change in position of the lesion centre obtained in the
experimental measurements and the distance between
the intended focus and the coordinates of the maximum
pressure point from the simulations are shown in Fig. 8.
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Fig. 8 Comparison between the focal shift obtained in simulations
and experiments. The error bars show the standard deviation of the
experiment results
Both simulations and experiments give similar values for
the magnitude and range of the effect of the marker. As
an example, the biggest change in position occurs with
the transducer focus positioned 4 mm behind the marker,
with a shift of 4-5 mm.
Transducer geometry
While the experimental results replicate the numerical
predictions, some limitations of this work are as follows.
Firstly, the HIFU transducer used in the experimental
study differs geometrically from the transducers used clin-
ically. For example, lesions generated with no markers
present using the Sonablate 500 probe are significantly
larger than the lesions produced by the H-101 transducer
used here (3 × 3 × 10 mm3 vs 1 × 1 × 3 mm3). However,
as the aperture for the Sonablate 500 transducer is smaller
(see Fig. 9), this means that proportionally, the marker will
interact with a larger portion of the HIFU beam. This sug-
gests the aberrations may be worse in the clinical scenario
compared to the results presented here, although the sim-
ulations using the clinical geometry, despite not modelling
the thermal aspect, show comparable effects.
Second, for clinical systems, cavitation effects also play
a role in tissue destruction, while only thermal lesions
have been considered here. While the reduction in focal
intensity due to the marker will likely also reduce the
onset and magnitude of cavitation activity, it is difficult to
infer exactly how this will relate to the results obtained in
this work.
Measurement uncertainties
Considering measurement uncertainties, the markers
in each phantom were positioned at slightly different
angles due to migration after insertion. This could have
influenced the size of the observed effect for any given
experiment, although it is unlikely to change the overall
Fig. 9 Schematic showing the effect different transducer geometries
have on the portion of the HIFU beam obstructed by the marker
distortion introduced by the marker. Also, the lesion vol-
ume was quantified assuming it had an ellipsoidal shape,
which may introduce errors for some lesion shapes (e.g.,
see Fig. 5). Finally, only one orientation of the marker
relative to the HIFU beam was investigated. For other ori-
entations (e.g., with the long axis of the marker aligned
with the beam axis), a different magnitude of the effect
might be observed.
Conclusion
The effect of a single EBRT fiducial marker on the
efficacy of HIFU treatment delivery was experimentally
investigated using a tissue-mimicking phantom and a
single element HIFU transducer. A modified recipe for
a prostate TMM was developed based on a polyacry-
lamide hydrogel containing bovine serum albumin. The
acoustic properties of the TMM were measured and
shown to be similar to the properties of the prostate. A
series of experiments were then conducted to investigate
the effect of the marker on the size and volume of the
generated lesion when the transducer focus is positioned
close to the marker. The results demonstrate that the
markers can significantly distort the shape, position,
and size of a HIFU lesion when positioned close to the
focus. This may result in an undertreated region beyond
the marker due to a reduction in energy arriving at the
focus, and an overtreated region in front of the marker
due to reflections. Depending on the position of the
targeted regions and the distribution of the markers,
both effects may be undesirable and may affect treatment
efficacy. Further work is needed using clinically available
prostate HIFU devices to assess the importance of these
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observations in clinical practice and to assess whether
it is necessary to reconsider patient selection and treat-
ment planning for prostate salvage HIFU after failed
EBRT. Whilst not explicitly studied, these results are
also relevant for salvage HIFU following brachytherapy,
where a large number of seeds (acoustically similar to
the gold EBRT fiducial markers) are implanted in the
prostate.
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